Until recently, attempts at creating a disease-modifying immunotherapy for type 1 diabetes produced negative results or transient success, said Jay S. Skyler, MD, MACP, FRCP, moderator of the Scientific Sessions symposium Implementing Type 1 Diabetes Immune Intervention in Clinical Practice.
Continua a leggere
New research presented at this year’s annual meeting of the European Association for the Study of Diabetes (EASD) shows that among people with type 1 diabetes who stopped working in the COVID-19 lockdown, blood sugar levels improved during the first week of lockdown despite having reduced opportunities for exercise and
Continua a leggere
While diabetes is established as a risk factor for severe SARS-CoV2 infection several important specific aspects need to be considered for people with type 1 diabetes. In contrast to older persons with diabetes, children, adolescents and young adults with type 1 diabetes are not at risk for unfavourable outcomes
Continua a leggere
A panel of investigators will present recent findings from the ongoing TEDDY (The Environmental Determinants of Diabetes in the Young) Study during the Virtual 80th Scientific Sessions symposium Update from the TEDDY Study at 8:00 a.m. CT Monday, June 15.
Continua a leggere
Dietary factors have been implicated for many years as potential pathophysiologic triggers in the development of type 1 diabetes (T1D). High intake of cereals and other gluten-containing products may lead to an increased risk for islet autoimmunity (IA)
Continua a leggere
An anti-CD3 antibody therapy significantly delayed onset of clinical diabetes in an at-risk population with diabetes autoantibodies. Because type 1 diabetes mellitus (DM) is the result of immune destruction of pancreatic islet cells, immunologic interventions have shown promise in delaying its onset.
Continua a leggere
